Young Kwang Chae, Professor and Co-Director of Developmental Therapeutics, Lurie Cancer Center at Northwestern University, shared a post on X:
“Lung-MAP continues to redefine lung cancer trials. Updates presented at our Spring SWOG lung committee meeting 2026. A master protocol enabling biomarker-driven and non-match studies in NSCLC-testing targeted therapies, ADCs, and immunotherapy strategies.
Why it matters:
- Flexible platform for rapid drug evaluation
- Broad collaboration (academia + industry + National Cancer Institute)
- Built-in biospecimen + data ecosystem
- Direct engagement with U.S. Food and Drug Administration
Impact:
- Faster activation – enrollment (~12 + 22 months)
- Nationwide reach + diverse participation
- Dozens of sub-studies, thousands screened
- Accelerating precision oncology at scale.”
Pembrolizumab Injection: Powerful 1-Minute Shift in Lung Cancer Care
